FierceBiotech

AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection

Nine in 10 people worldwide have been infected with Epstein-Barr virus (EBV). But only a small number will go on to develop serious illnesses that have been linked to the virus, such as lupus, chronic ...
Fierce Biotech

AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...
Hosted on MSN

AstraZeneca’s GEMINI-PeriOp GC Study: A New Frontier in Gastroesophageal Cancer Treatment

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ...
Investor's Business Daily on MSN

AstraZeneca reiterates $80 billion 2030 view ahead of 'catalyst-rich 2026'

AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.
KXAN

Study shows AstraZeneca pill can cut deaths from a type of lung cancer in half

AUSTIN (KXAN) – An AstraZeneca drug has been shown to reduce the risk of death in some lung cancer patients by more than half, according to the research. Results from a three-year-long clinical trial ...
The Globe and Mail

AstraZeneca’s Real‑World Osimertinib Study in Australia: What Investors Should Watch

Study Overview – AstraZeneca is sponsoring a completed retrospective study titled “A Retrospective Study of Treatment Patterns and Clinical Outcomes in Australian EGFR Mutant Advanced and Metastatic ...